Compare Stocks: SUPN, AXSM, CRNX, and BLTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$179.25 -1.5%	$208.73	$117.30 ▼ $260.19	$9.54B	0.86	673,651 shs	981,348 shs
BLTE Belite Bio	$159.56 -2.1%	$166.48	$72.65 ▼ $200.00	$6.56B	-1.23	203,207 shs	184,763 shs
CRNX Crinetics Pharmaceuticals	$84.95	$84.64	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
SUPN Supernus Pharmaceuticals	$42.38 +0.5%	$44.67	$40.51 ▼ $59.68	$2.46B	0.55	610,146 shs	738,469 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-1.26%	-7.12%	-10.24%	-25.48%	+53.55%
BLTE Belite Bio	-4.03%	-3.81%	+4.01%	+11.15%	+121.74%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	0.00%	+101.16%	+104.16%
SUPN Supernus Pharmaceuticals	-2.00%	-2.56%	-3.57%	-12.22%	-12.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$179.25 -1.5%	$208.73	$117.30 ▼ $260.19	$9.54B	0.86	673,651 shs	981,348 shs
BLTE Belite Bio	$159.56 -2.1%	$166.48	$72.65 ▼ $200.00	$6.56B	-1.23	203,207 shs	184,763 shs
CRNX Crinetics Pharmaceuticals	$84.95	$84.64	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
SUPN Supernus Pharmaceuticals	$42.38 +0.5%	$44.67	$40.51 ▼ $59.68	$2.46B	0.55	610,146 shs	738,469 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-1.26%	-7.12%	-10.24%	-25.48%	+53.55%
BLTE Belite Bio	-4.03%	-3.81%	+4.01%	+11.15%	+121.74%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	0.00%	+101.16%	+104.16%
SUPN Supernus Pharmaceuticals	-2.00%	-2.56%	-3.57%	-12.22%	-12.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.86	Moderate Buy	$275.84	53.89% Upside
BLTE Belite Bio	2.64	Moderate Buy	$218.73	37.08% Upside
CRNX Crinetics Pharmaceuticals	2.13	Hold	$83.44	-1.77% Downside
SUPN Supernus Pharmaceuticals	2.43	Hold	$62.83	48.26% Upside

Current Analyst Ratings Breakdown

Latest SUPN, AXSM, CRNX, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	AXSM Axsome Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$280.00 ➝ $267.00
9/25/2026	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$251.00 ➝ $247.00
9/25/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/23/2026	AXSM Axsome Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$200.00 ➝ $285.00
9/21/2026	SUPN Supernus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
9/18/2026	AXSM Axsome Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$258.00
9/9/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$220.00 ➝ $234.00
9/9/2026	BLTE Belite Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/8/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$245.00
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$776.57M	12.09	N/A	N/A	$1.75 per share	102.43
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
CRNX Crinetics Pharmaceuticals	$7.70M	1,170.54	N/A	N/A	$11.23 per share	7.56
SUPN Supernus Pharmaceuticals	$718.95M	3.43	$3.79 per share	11.17	$18.52 per share	2.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.75	N/A	47.42	N/A	-24.68%	-265.55%	-28.10%	11/2/2026 (Estimated)
BLTE Belite Bio	-$77.61M	-$2.73	N/A	175.34	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
SUPN Supernus Pharmaceuticals	-$38.55M	-$1.92	N/A	10.98	0.78	-13.23%	11.13%	8.10%	11/3/2026 (Estimated)

Latest SUPN, AXSM, CRNX, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	-$0.99	-$0.0980	-$0.99	$221.11 million	$218.38 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million
8/3/2026	Q2 2026 & Merger	SUPN Supernus Pharmaceuticals	$0.4225	-$1.01	-$1.4325	-$1.01	$205.31 million	$219.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.52	1.43	1.34
BLTE Belite Bio	N/A	33.56	33.56
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
SUPN Supernus Pharmaceuticals	N/A	2.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
BLTE Belite Bio	0.53%
CRNX Crinetics Pharmaceuticals	98.51%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
BLTE Belite Bio	13.29%
CRNX Crinetics Pharmaceuticals	3.80%
SUPN Supernus Pharmaceuticals	8.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	925	52.38 million	41.59 million	Optionable
BLTE Belite Bio	41	40.27 million	34.92 million	Not Optionable
CRNX Crinetics Pharmaceuticals	210	106.10 million	102.06 million	Optionable
SUPN Supernus Pharmaceuticals	778	58.22 million	53.28 million	Optionable

SUPN, AXSM, CRNX, and BLTE Headlines

Recent News About These Companies

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

September 24, 2026 | businesswire.com

Analysts Set Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Price Target at $62.83

September 23, 2026 | americanbankingnews.com

Bank of America Corp DE Buys New Stake in Supernus Pharmaceuticals, Inc. $SUPN

September 23, 2026 | marketbeat.com

Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

September 20, 2026 | finance.yahoo.com

Why Did Supernus Pharmaceuticals (SUPN) Move Today?

September 19, 2026 | finance.yahoo.com

How Supernus’ Q2 Beat and Raised Guidance Could Reshape Supernus Pharmaceuticals (SUPN) Investors’ Outlook

September 19, 2026 | finance.yahoo.com

Engineers Gate Manager LP Makes New $1.12 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN

September 19, 2026 | marketbeat.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Average Recommendation of "Hold" from Brokerages

September 18, 2026 | marketbeat.com

Indivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing

September 17, 2026 | quiverquant.comQ

Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month Low - What's Next?

September 15, 2026 | marketbeat.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 1-Year Low - Time to Sell?

September 8, 2026 | marketbeat.com

Jupiter Topco LLC Buys Shares of 23,254 Supernus Pharmaceuticals, Inc. $SUPN

September 6, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Invests $1.30 Million in Supernus Pharmaceuticals, Inc. $SUPN

September 5, 2026 | marketbeat.com

Legal & General Group Plc Purchases New Position in Supernus Pharmaceuticals, Inc. $SUPN

September 3, 2026 | marketbeat.com

Supernus Pharmaceuticals to Participate in September Investor Conferences

September 2, 2026 | globenewswire.com

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

August 31, 2026 | globenewswire.com

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

August 29, 2026 | businesswire.com

Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?

August 24, 2026 | zacks.com

Supernus Pharmaceuticals Inc

August 22, 2026 | money.usnews.com

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

August 21, 2026 | zacks.com

Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc., - M&A Call - Slideshow

August 7, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN, AXSM, CRNX, and BLTE Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$179.25 -2.82 (-1.55%)

Closing price 04:00 PM Eastern

Extended Trading

$178.50 -0.75 (-0.42%)

As of 07:30 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Belite Bio NASDAQ:BLTE

$159.56 -3.42 (-2.10%)

Closing price 04:00 PM Eastern

Extended Trading

$159.46 -0.09 (-0.06%)

As of 07:30 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.95 0.00 (0.00%)

As of 09/1/2026

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Supernus Pharmaceuticals NASDAQ:SUPN

$42.38 +0.20 (+0.47%)

As of 04:00 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SUPN, AXSM, CRNX, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SUPN, AXSM, CRNX, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SUPN, AXSM, CRNX, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN, AXSM, CRNX, and BLTE Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SUPN, AXSM, CRNX, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SUPN, AXSM, CRNX, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SUPN, AXSM, CRNX, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN, AXSM, CRNX, and BLTE Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

Supernus Pharmaceuticals NASDAQ:SUPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools